Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

GSK Fires China R&D Chief for Misrepresenting Data

publication date: Jun 12, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
According to GlaxoSmithKline, a scientific paper published by members of its China R&D staff contained “misrepresentations.”  The British biopharma has fired Jiangwu Zhang, the head of its China R&D operation, who was listed as one of the authors. The 2010 Nature Medicine article investigated the role of interleukin-7 in autoimmune diseases. As a result of the scandal, GSK has suspended Phase I tests of GSK2618960, an experimental medicine for multiple sclerosis that was based in part on the article’s early-stage research. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners